Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Saad Z. Usmani, MD, MBA, FACP
Dr. Usmani is Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York.
Articles by Saad Z. Usmani, MD, MBA, FACP
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
Saad Z. Usmani, MD, MBA, FACP
The HemOnc Pulse
|
November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Listen Now
'The HemOnc Pulse' Live: Key Takeaways in MRD, Smoldering Myeloma
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse Live
|
May 31, 2024
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
View More
Dr. Usmani Discusses Perseus Data Implications, Other Myeloma Updates
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse
|
January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Listen Now
Panel Highlights Key Myeloma Takeaways From ASCO 2023
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists highlight key data presented at ASCO 2023.
View More
What Are the Considerations with Toxicity, Access in BCMA-Directed Bispecifics?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
View More
Panel Discusses Use of Bispecifics to Treat Relapsed/Refractory Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
View More
What Are the Novel BCMA-Targeted CAR-T Therapies in the Myeloma Pipeline?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
View More
Real-World CAR-T Outcomes, Use of Ide-Cel, Cilta-Cel for Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
View More
Panelists Discuss Access to CAR-T for Patients with Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
View More
What Is the Role of BCMA-Targeted CAR-Ts in Late-Relapse Multiple Myeloma?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
View More
Panel Discusses Maintenance Therapy, the Changing Landscape for Early-Relapse Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
View More
Early Relapse: Three Versus Four Drugs for Induction in Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
View More
CAR-T Versus Bispecific Antibodies in Multiple Myeloma: Which Is the Better Option for Patients?
Thomas Martin, MD
Myeloma
|
February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Read More
Will CAR-T Therapy Replace AHSCT in Multiple Myeloma?
Amrita Krishnan, MD, FACP
Print
|
May 30, 2023
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Read More
Myeloma Roundtable: Optimal Treatment Sequencing
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
November 14, 2022
Experts discuss treatment options related to anti-CD38 based combination triplets.
View More
Myeloma Roundtable: BCMA-Targeting Therapies
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
November 14, 2022
Experts focus on the latest news and clinical development and impact for multiple myeloma.
View More
Myeloma Roundtable: COVID-19 in the Multiple Myeloma Patient
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
November 14, 2022
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
View More
Understanding the Patient’s Experience in Myeloma Care: A Conversation Between Myeloma Patients and a Myeloma Specialist
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
July 13, 2021
Communication, clarity, patient education, and support from the healthcare team can all contribute to adherence to therapy.
Read More
Saad Usmani Discusses Effective Treatment for Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
November 14, 2022
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
View More
Myeloma 101: Incidence, Disease Presentation, and Clinical Diagnosis
Saad Z. Usmani, MD, MBA, FACP
Myeloma
|
November 14, 2022
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Read More
Load More